Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B13 | Q7Z5P4 | 2/20 | 0.37 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.35 |
| ▸ | CD38 | P28907 | 1/20 | 0.34 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.33 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.33 |
| ▸ | ROCK2 | O75116 | 5/20 | 0.33 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.31 |
| ▸ | CNR1 | P21554 | 2/20 | 0.31 |
| ▸ | CNR2 | P34972 | 2/20 | 0.31 |
| ▸ | PDE1A | P54750 | 1/20 | 0.30 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.30 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31269102 | 0.91 | PIK3CD (0.35) | DGAT1PIK3CDROCK2GPR119CNR1 | |
| SCHEMBL31268747 | 0.88 | CNR1 (0.36) | DGAT1PIK3CDCNR1CNR2 | |
| SCHEMBL31269347 | 0.86 | PIK3CD (0.34) | DGAT1PIK3CDROCK2CNR1CNR2 | |
| SCHEMBL31269290 | 0.86 | PIK3CD (0.37) | DGAT1PIK3CDROCK2CNR1CNR2 | |
| SCHEMBL31268843 | 0.86 | GRM2 (0.38) | GRM2DGAT1PIK3CD | |
| SCHEMBL31269283 | 0.86 | PIK3CD (0.38) | DGAT1PIK3CDCNR1CNR2 | |
| SCHEMBL31268788 | 0.85 | PIK3CD (0.37) | GRM2DGAT1PIK3CDCNR1CNR2 | |
| SCHEMBL31269110 | 0.85 | PIK3CD (0.38) | GRM2DGAT1PIK3CDCNR1CNR2 | |
| SCHEMBL31269337 | 0.84 | CNR1 (0.39) | DGAT1PIK3CDGPR119CNR1CNR2 | |
| SCHEMBL31269014 | 0.84 | PIK3CD (0.34) | DGAT1PIK3CDCNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4689155-A1 | USE OF INHIBITORS TO INCREASE EFFICIENCY OF CRISPR/CAS INSERTIONS | Astrazeneca AB (SE) | 2026-02-11 | — | — | EP | disclosed |
| WO-2024201368-A1 | USE OF INHIBITORS TO INCREASE EFFICIENCY OF CRISPR/CAS INSERTIONS | ASTRAZENECA AB (SE) | 2024-10-03 | — | — | WO | disclosed |